11:23 AM EDT, 04/09/2024 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) said Tuesday that its Rezdiffra liver disease treatment is now available in the US.

Rezdiffra is indicated, with diet and exercise, for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis, Madrigal said.

The company said that the first patients have received the medication through its specialty pharmacy network.

Price: 246.71, Change: -1.93, Percent Change: -0.78